ORN Spring 2026: Update on the diversification of kratom-derived products: 7-hydroxymitragynine, pseudoindoxyl, and beyond-Handout - ORN Spring 2026

Handout - ORN Spring 2026 - Smith

Pdf Summary

This presentation reviewed the rapid diversification of kratom-derived products, especially 7-hydroxymitragynine (7-OH) and related compounds, with emphasis on pharmacology, use patterns, risks, and policy issues. Kratom’s main alkaloid, mitragynine (MG), and the metabolite 7-OH both act on mu-opioid receptors, though 7-OH has stronger binding and is thought to be more potent. Preclinical data suggest these substances can produce opioid-like effects and respiratory depression in animals, but human abuse-potential and safety data remain limited.<br /><br />The speaker highlighted the growing market and use of 7-OH in the U.S., noting survey and clinical-trial data suggesting millions of potential users. Reported sources of awareness and purchase included vape shops, online vendors, convenience stores, gas stations, and Reddit. Many users reported frequent dosing, rapid onset, effects lasting hours, and some unwanted effects; a subset sought medical care. A notable proportion used 7-OH as a substitute for kratom leaf or extract, and many described the effects as both habit-forming and beneficial.<br /><br />The talk also summarized toxicology and poison-center data. DEA toxicology cases and poison center exposures show increasing involvement of 7-OH-related products, though interpretation is complicated by co-occurring kratom alkaloids and voluntary reporting limitations. Regulatory attention is intensifying: in July 2025 the FDA recommended scheduling 7-OH as Schedule I, while the DEA had not yet taken public action at the time of the presentation.<br /><br />Overall, the key message was that demand for kratom-derived products is unlikely to disappear through scheduling alone, and clinicians should be prepared to assess use, intoxication, dependence, and treatment needs.

Keywords

kratom

7-hydroxymitragynine

mitragynine

mu-opioid receptors

opioid-like effects

respiratory depression

poison center exposures

toxicology

FDA scheduling

substance use patterns